通过阻断膜抗原的蛋白质体降解来提高CAR T细胞的效率
Leonie Rieger1, Kilian Irlinger1, Franziska Füchsl2
1Technical University of Munich, TUM University Hospital, München, Germany.
Blood
|July 10, 2025
概括
像卡菲尔佐米布这样的蛋白质酶抑制剂可以增强B细胞成熟抗原 (BCMA) 在多发性髓瘤细胞上的表达. 这一策略可能会改善化学抗原受体 (CAR) T 细胞治疗在初始治疗后复发的患者的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 化学抗原受体 (CAR) T细胞疗法对B细胞恶性瘤有希望,但由于抗原损失,通常会失败.
- B细胞成熟抗原 (BCMA) 是多发性骨髓瘤 (MM) 中CAR T细胞的关键标.
研究的目的:
- 研究调节MM细胞上BCMA表达的机制.
- 探索增强BCMA表达的策略,以提高CAR T细胞治疗的疗效.
主要方法:
- 鉴定出BCMA是一种短命的蛋白质,被ubiquitin-proteasome系统 (UPS) 降解.
- 使用蛋白酶体抑制剂 (PI),包括卡菲尔佐米布 (CFZ),以调节BCMA水平.
- 评估了BCMA导向的CAR T细胞与CFZ结合的MM的体外和体外模型的疗效.
- 在MM患者中评估BCMA表达,在CAR T细胞治疗后接受CFZ复发后治疗.
主要成果:
- BCMA经历K48结合的多比基化和p97依赖的降解在等离子体膜.
- 蛋白质酶抑制剂,特别是CFZ,显著增强BCMA表面表达.
- CFZ治疗改善了BCMA CAR T细胞对MM细胞的疗效.
- 在患者中,CFZ增加了BCMA表达,临床反应与剩余的CAR T细胞活性相关.
结论:
- 通过UPS进行BCMA调节提供了一种可向的机制,以增强CAR T细胞治疗.
- 卡菲尔佐米布在BCMA CAR T细胞治疗后,在复发性/耐药性多发性髓瘤中显示出组合治疗的潜力.
- 这项研究为向其他免疫疗法抗原降解途径提供了一个框架.
相关概念视频
Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
T Cell Activation and Clonal Selection
5.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
5.5K
Cell-mediated Immune Responses
73.5K
Overview
73.5K
Cytotoxic T Cells-mediated Immune Response
2.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.4K
Antigens Involved in Adaptive Immunity
694
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
694
B Cell Activation and Differentiation
6.5K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
6.5K


